Systemic sclerosis & Raynaud's
Bosentan effect on echocardiographic systolic pulmonary arterial pressure in systemic sclerosis-related pulmonary hypertension: a systematic review and metanalysis
Pooled result · sPAP, mean difference before and after bosentanResult — go to the resultMean difference - 5.63 mmHg 95% CI −9.79 to −1.48Authors' conclusion
Bosentan significantly decreases sPAP, a relevant prognostic marker, especially in overt SSc-PAH. However, bosentan did not decrease sPAP when started for DU/mixed indication nor for follow-up>1 year. The burden of publication bias was significant.
Study context
- Population
- SSc patients treated with bosentan with systolic pulmonary arterial pressure (sPAP) measured at transthoracic echocardiography; studies January 2000 to June 2023, three databases11 manuscripts
- Comparison
- SSc patients after vs before starting bosentan
- Outcome
- Echocardiographic sPAP reduction with bosentan
Methodological detailsrandom-effects meta-analysis, Egger's test for publication bias, stratified analysis
- Random-effects meta-analysis
- Egger's test for publication bias
- Stratified analysis
Pooled result
sPAP, mean difference before and after bosentan
Mean difference
- 5.63 mmHg
95% CI −9.79 to −1.48
P = 0.0078
After bosentanvs Before bosentan
mean difference - 5.63 mmHg (95% CI −9.79 to −1.48); P = 0.0078
As reported in the abstract
Further pooled results
sPAP before vs after bosentan, stratified analysis
- Significant only for studies with < 1 year of follow-up
- P = 0.0020
- Significant for monotherapy
- P = 0.0140
- Significant for strict indication for pulmonary arterial hypertension (PAH)
- P = 0.0002
Original publication
Bosentan effect on echocardiographic systolic pulmonary arterial pressure in systemic sclerosis-related pulmonary hypertension: a systematic review and metanalysis. Clin Exp Rheumatol. Published 19 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →